Becton, Dickinson and Co. | BDX - Sales Revenues

Stock Price
150.22
Daily Change
-1.92 -1.26%
Monthly
-2.89%
Yearly
-26.59%
Q2 Forecast
148.88

Becton, Dickinson and Co. reported $5.3B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Agilent USD 1.8B 63M Dec/2025
Align Technology USD 1.05B 54.3M Dec/2025
AngioDynamics USD 79.43M 3.72M Sep/2025
Avanos Medical USD 180.9M 3.1M Dec/2025
Baxter International USD 2.97B 130M Dec/2025
Becton, Dickinson and Co. USD 5.3B 600M Dec/2025
Bio-Rad Laboratories USD 693.2M 40.2M Dec/2025
Boston Scientific USD 5.2B 90M Mar/2026
Cooper Companies USD 1.02B 41.1M Dec/2025
Danaher USD 5.95B 890M Mar/2026
Dentsply International USD 961M 57M Dec/2025
Dexcom USD 1.26B 50M Dec/2025
Edwards Lifesciences USD 1.65B 80M Mar/2026
Globus Medical USD 826.4M 57.4M Dec/2025
Insulet USD 783.8M 77.5M Dec/2025
Integra LifeSciences USD 434.9M 32.84M Dec/2025
Intuitive Surgical USD 2.77B 100M Mar/2026
J&J USD 24.1B 500M Mar/2026
Masimo USD 412.5M 41M Dec/2025
Medtronic USD 9B 39M Jan/2026
Solventum Corp USD 1.99B 110M Dec/2025
Stryker USD 7.2B 1.14B Dec/2025
Tandem Diabetes Care USD 290.4M 41.15M Dec/2025
Teleflex USD 568.98M 344.02M Dec/2025
Terumo JPY 296.63B 21.66B Dec/2025
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Zimmer Biomet Holdings USD 2.24B 240M Dec/2025